What an 'Essential Health Benefit' Designation Would Mean for GLP-1 Coverage
Essential health benefit categories shape what ACA-compliant plans must cover. Here's how that framework interacts with anti-obesity medication coverage debates.
By the GLP Semaglutide editorial team · Last updated June 2, 2025
The Affordable Care Act defines ten categories of 'essential health benefits' that ACA-compliant individual and small-group plans must cover in some form, with specific covered services and drugs within each category determined by state benchmark plans.
Where anti-obesity medication fits, or doesn't
Whether a specific anti-obesity medication is covered under a state's essential health benefit benchmark plan varies, and this framework applies specifically to ACA marketplace and small-group plans — a different coverage question from Medicare, Medicaid, or large self-insured employer plans discussed elsewhere in this section.
A live policy debate
Advocacy groups have pushed for clearer inclusion of anti-obesity medications in essential health benefit frameworks; whether and how that happens is an ongoing regulatory and legislative question best tracked through CMS's own benchmark plan guidance.
Primary sources